CONTEXT: NRG1 is a schizophrenia candidate gene and plays an important role in brain development and neural function. Schizophrenia is a complex disorder, with etiology likely due to epistasis. OBJECTIVE: To examine epistasis between NRG1 and selected N-methyl-d-aspartate-glutamate pathway partners implicated in its effects, including ERBB4, AKT1, DLG4, NOS1, and NOS1AP. DESIGN: Schizophrenia case-control sample analyzed using machine learning algorithms and logistic regression with follow-up using neuroimaging on an independent sample of healthy controls. PARTICIPANTS: A referred sample of schizophrenic patients (n = 296) meeting DSM-IV criteria for schizophrenia spectrum disorder and a volunteer sample of controls for case-control comparison (n = 365) and a separate volunteer sample of controls for neuroimaging (n = 172). MAIN OUTCOME MEASURES: Epistatic association between single-nucleotide polymorphisms (SNPs) and case-control status; epistatic association between SNPs and the blood oxygen level-dependent physiological response during working memory measured by functional magnetic resonance imaging. RESULTS: We observed interaction between NRG1 5' and 3' SNPs rs4560751 and rs3802160 (likelihood ratio test P = .00020) and schizophrenia, which was validated using functional magnetic resonance imaging of working memory in healthy controls; carriers of risk-associated genotypes showed inefficient processing in the dorsolateral prefrontal cortex (P = .015, familywise error corrected). We observed epistasis between NRG1 (rs10503929; Thr286/289/294Met) and its receptor ERBB4 (rs1026882; likelihood ratio test P = .035); a 3-way interaction with these 2 SNPs and AKT1 (rs2494734) was also observed (odds ratio, 27.13; 95% confidence interval, 3.30-223.03; likelihood ratio test P = .042). These same 2- and 3-way interactions were further biologically validated via functional magnetic resonance imaging: healthy individuals carrying risk genotypes for NRG1 and ERBB4, or these 2 together with AKT1, were disproportionately less efficient in dorsolateral prefrontal cortex processing. Lower-level interactions were not observed between NRG1 /ERBB4 and AKT1 in association or neuroimaging, consistent with biological evidence that NRG1 × ERBB4 interaction modulates downstream AKT1 signaling. CONCLUSION: Our data suggest complex epistatic effects implicating an NRG1 molecular pathway in cognitive brain function and the pathogenesis of schizophrenia.
CONTEXT: NRG1 is a schizophrenia candidate gene and plays an important role in brain development and neural function. Schizophrenia is a complex disorder, with etiology likely due to epistasis. OBJECTIVE: To examine epistasis between NRG1 and selected N-methyl-d-aspartate-glutamate pathway partners implicated in its effects, including ERBB4, AKT1, DLG4, NOS1, and NOS1AP. DESIGN:Schizophrenia case-control sample analyzed using machine learning algorithms and logistic regression with follow-up using neuroimaging on an independent sample of healthy controls. PARTICIPANTS: A referred sample of schizophrenicpatients (n = 296) meeting DSM-IV criteria for schizophrenia spectrum disorder and a volunteer sample of controls for case-control comparison (n = 365) and a separate volunteer sample of controls for neuroimaging (n = 172). MAIN OUTCOME MEASURES: Epistatic association between single-nucleotide polymorphisms (SNPs) and case-control status; epistatic association between SNPs and the blood oxygen level-dependent physiological response during working memory measured by functional magnetic resonance imaging. RESULTS: We observed interaction between NRG1 5' and 3' SNPs rs4560751 and rs3802160 (likelihood ratio test P = .00020) and schizophrenia, which was validated using functional magnetic resonance imaging of working memory in healthy controls; carriers of risk-associated genotypes showed inefficient processing in the dorsolateral prefrontal cortex (P = .015, familywise error corrected). We observed epistasis between NRG1 (rs10503929; Thr286/289/294Met) and its receptor ERBB4 (rs1026882; likelihood ratio test P = .035); a 3-way interaction with these 2 SNPs and AKT1 (rs2494734) was also observed (odds ratio, 27.13; 95% confidence interval, 3.30-223.03; likelihood ratio test P = .042). These same 2- and 3-way interactions were further biologically validated via functional magnetic resonance imaging: healthy individuals carrying risk genotypes for NRG1 and ERBB4, or these 2 together with AKT1, were disproportionately less efficient in dorsolateral prefrontal cortex processing. Lower-level interactions were not observed between NRG1 /ERBB4 and AKT1 in association or neuroimaging, consistent with biological evidence that NRG1 × ERBB4 interaction modulates downstream AKT1 signaling. CONCLUSION: Our data suggest complex epistatic effects implicating an NRG1 molecular pathway in cognitive brain function and the pathogenesis of schizophrenia.
Authors: Nicole C Allen; Sachin Bagade; Matthew B McQueen; John P A Ioannidis; Fotini K Kavvoura; Muin J Khoury; Rudolph E Tanzi; Lars Bertram Journal: Nat Genet Date: 2008-07 Impact factor: 38.330
Authors: J E Brenman; D S Chao; S H Gee; A W McGee; S E Craven; D R Santillano; Z Wu; F Huang; H Xia; M F Peters; S C Froehner; D S Bredt Journal: Cell Date: 1996-03-08 Impact factor: 41.582
Authors: D R Weinberger; M F Egan; A Bertolino; J H Callicott; V S Mattay; B K Lipska; K F Berman; T E Goldberg Journal: Biol Psychiatry Date: 2001-12-01 Impact factor: 13.382
Authors: Brian K Suarez; Jubao Duan; Alan R Sanders; Anthony L Hinrichs; Carol H Jin; Cuiping Hou; Nancy G Buccola; Nancy Hale; Ann N Weilbaecher; Deborah A Nertney; Ann Olincy; Susan Green; Arthur W Schaffer; Christopher J Smith; Dominique E Hannah; John P Rice; Nancy J Cox; Maria Martinez; Bryan J Mowry; Farooq Amin; Jeremy M Silverman; Donald W Black; William F Byerley; Raymond R Crowe; Robert Freedman; C Robert Cloninger; Douglas F Levinson; Pablo V Gejman Journal: Am J Hum Genet Date: 2006-01-03 Impact factor: 11.025
Authors: Andrés Ingason; Karen Søeby; Sally Timm; August G Wang; Klaus D Jakobsen; Anders Fink-Jensen; Ralf Hemmingsen; Henrik Berg Rasmussen; Thomas Werge Journal: Schizophr Res Date: 2006-02-17 Impact factor: 4.939
Authors: A P Corvin; D W Morris; K McGhee; S Schwaiger; P Scully; J Quinn; D Meagher; D St Clair; J L Waddington; M Gill Journal: Mol Psychiatry Date: 2004-02 Impact factor: 15.992
Authors: Linda M Brzustowicz; Jaime Simone; Paria Mohseni; Jared E Hayter; Kathleen A Hodgkinson; Eva W C Chow; Anne S Bassett Journal: Am J Hum Genet Date: 2004-04-02 Impact factor: 11.025
Authors: Nadine Norton; Valentina Moskvina; Derek W Morris; Nicholas J Bray; Stanley Zammit; Nigel M Williams; Hywel J Williams; Anna C Preece; Sarah Dwyer; Jennifer C Wilkinson; Gillian Spurlock; George Kirov; Paul Buckland; John L Waddington; Michael Gill; Aiden P Corvin; Michael J Owen; Michael C O'Donovan Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2006-01-05 Impact factor: 3.568
Authors: Omid Kohannim; Neda Jahanshad; Meredith N Braskie; Jason L Stein; Ming-Chang Chiang; April H Reese; Derrek P Hibar; Arthur W Toga; Katie L McMahon; Greig I de Zubicaray; Sarah E Medland; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Paul M Thompson Journal: Neuropsychopharmacology Date: 2012-04-18 Impact factor: 7.853
Authors: Olga I Dadalko; Michael Siuta; Amanda Poe; Kevin Erreger; Heinrich J G Matthies; Kevin Niswender; Aurelio Galli Journal: J Neurosci Date: 2015-06-10 Impact factor: 6.167
Authors: Deanna L Kelly; Xin Li; Catherine Kilday; Stephanie Feldman; Sarah Clark; Fang Liu; Robert W Buchanan; Leonardo H Tonelli Journal: Psychiatry Res Date: 2018-09-05 Impact factor: 3.222
Authors: Jeremy M Veenstra-Vanderweele; Aurelio Galli; Christine Saunders; Michael Siuta; Sabrina D Robertson; Adeola R Davis; Jennifer Sauer; Heinrich J G Matthies; Paul J Gresch; David Airey; Craig W Lindsley; John A Schetz; Kevin D Niswender Journal: Neurochem Int Date: 2013-09-30 Impact factor: 3.921